China CHAMP是一项随机、双盲、安慰剂平行对照、多中心、第III期临床研究，其主要目标为评估NVK002(0.01%及0.02%的低剂量阿托品)对治疗中国儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心，入组777名患者。Zhaoke Ophthalmology-B (06622) opened over 9%, as of the deadline, rose 9.56%, at 1.49 Hong Kong dollars, with a turnover of 0.2213 million Hong Kong dollars.
According to the Wise Finance APP, Zhaoke Ophthalmology-B (06622) opened over 9%, as of the deadline, rose 9.56%, at 1.49 Hong Kong dollars, with a turnover of 0.2213 million Hong Kong dollars.
On the news front, Zhaoke Ophthalmology-B announced that the topline results of the third phase III clinical trial of NVK002 (one of the company's core products) will be conducted over a two-year period. After two years of treatment, the analysis of this study showed that the NVK002 eye drop group (0.01% and 0.02% doses) had a statistically significant difference in the main efficacy indicators compared to the placebo group. The NVK002 eye drop group outperformed the placebo group and showed dose dependency. Both doses of NVK002 were well-tolerated, and patients demonstrated good compliance with use.
China CHAMP is a randomized, double-blind, placebo-controlled, multicenter, Phase III clinical study with the main objective of evaluating the efficacy and safety of NVK002 (low doses of atropine at 0.01% and 0.02%) in treating myopia progression in Chinese children and adolescents. The trial involved 18 centers and enrolled 777 patients.
